Compass Therapeutics Investor Presentation Deck

CTX-8371: Development Status IND enabling activities NHP dose range finding study completed → PD-1 shedding confirmed in vivo Manufacturing campaign completed Pre-IND meeting completed Toxicology studies underway COMPASS THERAPEUTICS O Phase 1 study planning Multiple ascending dose, dose-escalation study 5 doses planned: 0.1, 0.3, 1.0, 3.0, and 10 mg/kg Post PD-1 or PD-L1 patient population PD-1 shedding on peripheral T cells was confirmed in NHP IND submission targeted for H1 2023 Potential for proprietary combination regimens with CTX-009 and CTX-471 37

View entire presentation